• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钠离子通道阻滞剂吡西卡尼对心房颤动患者肺静脉电生理特性的影响。

Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation.

作者信息

Kumagai Koichiro, Tojo Hideaki, Noguchi Hiroo, Yasuda Tomoo, Ogawa Masahiro, Nakashima Hideko, Zhang Bo, Saku Keijiro

机构信息

Department of Cardiology, Fukuoka University Hospital, Fukuoka, Japan.

出版信息

J Cardiovasc Electrophysiol. 2004 Dec;15(12):1396-401. doi: 10.1046/j.1540-8167.2004.04430.x.

DOI:10.1046/j.1540-8167.2004.04430.x
PMID:15610286
Abstract

INTRODUCTION

Na+ channel blockers are used to treat atrial fibrillation (AF). However, the effects of Na+ channel blockers on the electrophysiologic properties of pulmonary veins (PVs) are not well characterized. The aim of the present study was to evaluate the effect of the pure Na+ channel blocker pilsicainide on the PVs.

METHODS AND RESULTS

PV mapping using a basket catheter was performed in 28 patients with paroxysmal AF. Twenty-eight PVs, including 20 left superior and 8 right superior PVs, were studied. Programmed stimulation was performed in the distal PV and PV-left atrial (LA) junction before and after infusion of pilsicainide (1 mg/kg). Pilsicainide significantly prolonged the effective refractory period (ERP) of the distal PV from 163 +/- 44 msec to 192 +/- 53 msec (P < 0.001), PV-LA junction from 227 +/- 48 msec to 235 +/- 52 msec (P < 0.05), and LA appendage from 225 +/- 55 msec to 245 +/- 48 msec (P < 0.05). Pilsicainide significantly prolonged the conduction time from the distal PV to PV-LA junction from 45 +/- 14 msec to 70 +/- 26 msec (P < 0.0001). In 3 of 5 patients who experienced AF termination with pilsicainide, PV-LA conduction block was observed just before AF termination.

CONCLUSIONS

Pilsicainide can modify ERP heterogeneity and conduction properties in the PV and at the PV-LA junction. Because the PV and PV-LA junction have important roles as substrates for AF maintenance, pilsicainide may terminate AF by pharmacologic PV isolation.

摘要

引言

钠离子通道阻滞剂用于治疗心房颤动(AF)。然而,钠离子通道阻滞剂对肺静脉(PVs)电生理特性的影响尚未得到充分阐明。本研究的目的是评估纯钠离子通道阻滞剂吡西卡尼对肺静脉的作用。

方法与结果

对28例阵发性房颤患者使用篮状导管进行肺静脉标测。研究了28条肺静脉,包括20条左上肺静脉和8条右上肺静脉。在输注吡西卡尼(1mg/kg)前后,在肺静脉远端和肺静脉-左心房(LA)交界处进行程控刺激。吡西卡尼显著延长了肺静脉远端的有效不应期(ERP),从163±44毫秒延长至192±53毫秒(P<0.001),肺静脉-左心房交界处从227±48毫秒延长至235±52毫秒(P<0.05),左心耳从225±55毫秒延长至245±48毫秒(P<0.05)。吡西卡尼显著延长了从肺静脉远端到肺静脉-左心房交界处的传导时间,从45±14毫秒延长至70±26毫秒(P<0.0001)。在5例使用吡西卡尼终止房颤的患者中,有3例在房颤终止前观察到肺静脉-左心房传导阻滞。

结论

吡西卡尼可改变肺静脉及肺静脉-左心房交界处的ERP异质性和传导特性。由于肺静脉及肺静脉-左心房交界处作为房颤维持的基质具有重要作用,吡西卡尼可能通过药物性肺静脉隔离来终止房颤。

相似文献

1
Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation.钠离子通道阻滞剂吡西卡尼对心房颤动患者肺静脉电生理特性的影响。
J Cardiovasc Electrophysiol. 2004 Dec;15(12):1396-401. doi: 10.1046/j.1540-8167.2004.04430.x.
2
Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter.使用多电极篮状导管评估肺静脉的电生理特性。
J Am Coll Cardiol. 2004 Jun 16;43(12):2281-9. doi: 10.1016/j.jacc.2004.01.051.
3
Impact of amiodarone on electrophysiologic properties of pulmonary veins in patients with paroxysmal atrial fibrillation.胺碘酮对阵发性心房颤动患者肺静脉电生理特性的影响。
J Cardiovasc Electrophysiol. 2005 Jan;16(1):39-44. doi: 10.1046/j.1540-8167.2005.04418.x.
4
Pilsicainide for atrial fibrillation.吡西卡尼用于治疗心房颤动。
Drugs. 2006;66(16):2067-73. doi: 10.2165/00003495-200666160-00003.
5
Mechanism of the conversion of a pulmonary vein tachycardia to atrial fibrillation in normal canine hearts: role of autonomic nerve stimulation.正常犬心脏中肺静脉心动过速转变为心房颤动的机制:自主神经刺激的作用。
J Cardiovasc Electrophysiol. 2007 May;18(5):534-41. doi: 10.1111/j.1540-8167.2007.00772.x. Epub 2007 Feb 21.
6
Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study.阵发性心房颤动患者左心房顶部线性阻滞的技术、评估及后果:一项前瞻性随机研究
Circulation. 2005 Dec 13;112(24):3688-96. doi: 10.1161/CIRCULATIONAHA.105.541052.
7
Atrial fibrillation and effective refractory period of the pulmonary vein ostia.心房颤动与肺静脉口有效不应期
Rev Port Cardiol. 2002 Oct;21(10):1125-34.
8
Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect.吡西卡尼对心房颤动时右心房、左心房及肺静脉主导频率的影响:与其终止心房颤动作用的相关性
Eur J Pharmacol. 2009 Apr 17;608(1-3):54-61. doi: 10.1016/j.ejphar.2009.02.040. Epub 2009 Mar 5.
9
High-density mapping of spontaneous pulmonary vein activity initiating atrial fibrillation in humans.人类房颤发作时起始性肺静脉活动的高密度标测
J Cardiovasc Electrophysiol. 2007 Jan;18(1):31-8. doi: 10.1111/j.1540-8167.2006.00682.x.
10
Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation.吡西卡尼与肺静脉隔离联合治疗心房颤动。
Circ J. 2005 Dec;69(12):1503-7. doi: 10.1253/circj.69.1503.

引用本文的文献

1
Automaticity of the Pulmonary Vein Myocardium and the Effect of Class I Antiarrhythmic Drugs.肺静脉心肌的自律性和 I 类抗心律失常药物的作用。
Int J Mol Sci. 2024 Nov 18;25(22):12367. doi: 10.3390/ijms252212367.
2
Atrial Fibrillation and Underlying Structural and Electrophysiological Heterogeneity.心房颤动及潜在的结构和电生理异质性。
Int J Mol Sci. 2024 Sep 23;25(18):10193. doi: 10.3390/ijms251810193.
3
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.《日本循环学会/日本心律学会2020年心律失常药物治疗指南》
J Arrhythm. 2022 Oct 25;38(6):833-973. doi: 10.1002/joa3.12714. eCollection 2022 Dec.
4
Atrial fibrillation type modulates the clinical predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation recurrence after catheter ablation.房颤类型调节中性粒细胞与淋巴细胞比值对导管消融术后房颤复发的临床预测价值。
Int J Cardiol Heart Vasc. 2020 Oct 28;31:100664. doi: 10.1016/j.ijcha.2020.100664. eCollection 2020 Dec.
5
Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.维纳卡兰用于心房颤动急性复律的安全性和有效性:最新进展
Vasc Health Risk Manag. 2013;9:165-75. doi: 10.2147/VHRM.S43720. Epub 2013 Apr 23.
6
Pilsicainide.吡司卡尼。
Drugs. 2010 Mar 5;70(4):455-67. doi: 10.2165/11204960-000000000-00000.
7
Pilsicainide for atrial fibrillation.吡西卡尼用于治疗心房颤动。
Drugs. 2006;66(16):2067-73. doi: 10.2165/00003495-200666160-00003.